Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates

Core Viewpoint - Theravance Biopharma reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of $0.03 per share, marking a significant improvement from a loss of $0.06 per share a year ago, resulting in an earnings surprise of +233.33% [1] Financial Performance - The company achieved revenues of $19.99 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.08%, compared to revenues of $16.87 million in the same quarter last year [2] - Over the last four quarters, Theravance Biopharma has exceeded consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Theravance Biopharma shares have increased approximately 56.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 14.4% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.21 on revenues of $59.99 million, while for the current fiscal year, the estimate is -$0.08 on revenues of $121.29 million [7] - The outlook for the Medical - Drugs industry, in which Theravance operates, is favorable, ranking in the top 37% of over 250 Zacks industries, suggesting potential for outperformance [8]